Discover how our integrated approach to analysing world Healthcare markets gives you the insight you need to inform critical decisions.


CRISPR Patent Fight Just Beginning

The patent fight between two different sets of CRISPR/Cas9 licensees will be drawn out, but will likely end in a cross-licensing agreement. 2017 will be a big year for the CRISPR technology as it enters clinical trials, with Editas Medicine aiming to have the first therapy in the clinic, which will bolster the company's potential. However, its competitors will not be far behind, and there is still significant scope for failure.





Jamie Davies

Head of Pharmaceuticals, Medical Devices and Healthcare Research
Pharmaceuticals & Healthcare | London

Kaushal Shah

Head of Pharmaceuticals and Healthcare Research
Pharmaceuticals & Healthcare | London


By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.